Novo Nordisk | NVO - Sales Revenues

Stock Price
46.60
Daily Change
3.28 7.57%
Monthly
-17.58%
Yearly
-46.06%
Q1 Forecast
56.42

Novo Nordisk reported DKK12.53B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
ANI Pharmaceuticals USD 227.81M 16.44M Sep/2025
Aurora Cannabis CAD 90.37M 7.65M Sep/2025
Bausch Health Companies USD 2.68B 150M Sep/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Canopy Growth CAD 66.68M 5.45M Sep/2025
Corcept Therapeutics USD 207.6M 13.2M Sep/2025
Drreddys Laboratories INR 87.27B 1.82B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Merck USD 16.4B 880M Dec/2025
Novartis USD 13.91B 144M Sep/2025
Novo Nordisk DKK 79.14B 4.16B Dec/2025
Novo Nordisk DKK 12.53B 560M Dec/2025
Pacira USD 179.52M 1.58M Sep/2025
Perrigo USD 1.04B 16.3M Sep/2025
Prestige Brands USD 283.44M 9.34M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Supernus Pharmaceuticals USD 192.1M 26.6M Sep/2025
Zoetis USD 2.4B 60M Sep/2025